Ramipril Capsule
Product Images NDC 72789-415

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Ramipril (NDC 72789-415). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Pd-rx Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

72789415 Label (72789415)

This is a medication information sheet for Ramipril capsules, each containing 2.5mg of Ramipril. The pack contains 90 capsules with an expiration date of 01/2025. It includes instructions to take the capsule(s) daily and advises to contact a doctor for medical advice regarding side effects. The label also provides information to report side effects to the FDA. It is essential to discontinue use if pregnancy is detected.*

FDA Label Image

Structured Product Formula For Ramipril (F36e6ac7 0cfb 4450 A2f2 84064a9c7d3a 01)

FDA Label Image

Figure 1 (F36e6ac7 0cfb 4450 A2f2 84064a9c7d3a 02)

This text presents Kaplan-Meier estimates comparing the composite outcome of myocardial infarction, stroke, or cardiovascular-related death between a group taking Ramipril and a group taking a placebo. The graph shows the relationship over time, with days of follow-up along the x-axis. The results suggest a significant difference (P=0.0001) between the outcomes in the Ramipril group and the placebo group.*

FDA Label Image

Figure 2 (F36e6ac7 0cfb 4450 A2f2 84064a9c7d3a 03)

The text provides a comparison of the beneficial effect of treatment with Ramipril on the composite outcome of myocardial infarction, stroke, or death from cardiovascular causes in different subgroups. The data includes information on the incidence of the composite outcome in various groups such as cardiovascular disease, diabetes, age groups, sex, hypertension, history of coronary artery disease, prior myocardial infarction, cerebrovascular disease, peripheral vascular disease, and microalbuminuria. The findings suggest that Ramipril treatment may have a positive impact on reducing these cardiovascular events in different patient subgroups.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.